Anergis
Developing novel allergy vaccines targeting the most common allergies
Anergis has raised €31M across 3 funding rounds from 3 investors, most recently a Series C round in Apr 2016. Based in Epalinges, Switzerland; active in Healthtech. Data as of 28 Oct 2026.
Epalinges, Switzerlandanergis.ch ↗
Total raised
€31M
€31,073,477
Funding rounds
3
Investors
3
distinct backers
Active since
2011-03
latest 2016-04
Funding by year
EUR raised per yearAnergis — funding by year — interactive chart.
Data table
| Anergis — funding by year | |
|---|---|
| 2011 | €14M |
| 2014 | €12M |
| 2016 | €4.6M |
Signals
Medium confidenceRaise-next likelihood9
base rate 50% for Series C
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Down/flat last round
Exit likelihood9
base rate 11% (2+ rounds)
- ▲ €30M+ raised
- ▼ No recent equity round (debt-only or quiet)
Timing: dormant vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
3 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2016-04-01 | Series C | €4.6M | — | View deal → |
| 2014-12-01 | Series B | €12M | — | View deal → |
| 2011-03-01 | Series A | €14M | BioMedPartners,Sunstone Capital,Vinci Capital | View deal → |
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Climeworks€919MSwitzerland · Cleantech
Global coverage: FundingData